Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 218

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 218
---
 a single-layer, drug-in-adhesive topical delivery system comprised of an adhesive material containing 36 mg lidocaine, which is applied to a pliable nonwoven cloth backing and covered with a
polyethylene terephthalate film release liner. ZTlido is commercially manufactured for us by Oishi in Japan. We license the rights to ZTlido from and rely exclusively on Oishi and Itochu pursuant to the Product Development Agreement, and the
Commercial Supply Agreement. We have exclusive worldwide rights to Oishi’s proprietary formulation and manufacturing technologies except with respect to Japan. In 2024, there were more than 206 million prescription lidocaine patches sold
in the United States, according to Symphony Healthcare.

We launched our second commercial product, ELYXYB in April 2023. We acquired the rights to certain patents, trademarks, regulatory approvals, data, contracts, and other rights related to
ELYXYB (celecoxib oral solution) and the commercialization thereof in the United States and Canada from BioDelivery Sciences International, Inc. and Collegium Pharmaceutical, Inc. in February
2023. ELYXYBis a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. We filed a New Drug Submission to Health Canada’s Pharmaceutical Drugs
Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for the approval of ELYXYB for acute treatment of migraine with or without aura in Canada.

137

We launched our third commercial product, GLOPERBA, in June 2024. We acquired certain rights
to GLOPERBA and the exclusive license to use the trademark “GLOPERBA”, pursuant to the Romeg License Agreement we entered into with Romeg, dated as of June 14, 2022, which
agreement was subsequently amended on January 16, 2025. GLOPERBA is an FDA-approved, liquid, oral medication for the treatment of gout in adults. Gout is a painful arthritic disorder affecting an
estimated 9.2 million people in the United States. Gout pain can be excruciating and is a form of inflammatory arthritis that develops in some people who have high levels of uric acid in their blood. It can cause sudden severe episodes of pain
and can be disabling with tenderness, warmth and swelling. Non-steroidal anti-inflammatory drugs, colchicine and cort